DEXTENZA Compared to Topical Steroid Therapy Prior to Cataract Surgery in Patients Who Receive Premium Intraocular Lenses

  • STATUS
    Recruiting
  • End date
    Sep 26, 2022
  • participants needed
    30
  • sponsor
    Prism Vision Group
Updated on 26 March 2021

Summary

The investigators seek to assess the effect of pre-operative and continued post-operative corticosteroid use on pain, patient preference, visual outcomes, and change in objective quantifiable biological parameters in patients undergoing bilateral cataract surgery with premium intraocular lens implantation with or without baseline ocular surface disease.

Patient's first eye scheduled for surgery will receive an intracanalicular insertion of DEXTENZA (dexamethasone release profile of QID, TID, BID, QD, over 30 days; study eye). The fellow-eye will receive topical prednisolone acetate 1% (tapering schedule of QID, TID, BID, QD over 30 days). The fellow-eye design in n=30 patients (60 eyes) allows for balance in patient baseline demographic and systemic characteristics.

Details
Condition Cataract, Cataracts, Cataracts
Treatment Dexamethasone, Prednisolone Acetate 1% Oph Susp
Clinical Study IdentifierNCT04479748
SponsorPrism Vision Group
Last Modified on26 March 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Age 18 or greater with plans to undergo bilateral clear cornea cataract surgery with phacoemulsification and implantation of a premium posterior chamber IOL
Schirmer's test score (anesthetized) 5 mm at Screening in either eye
TBUT 7 seconds at Screening or Baseline in either eye
All subjects must provide signed written consent prior to participation in any study-related procedures. Able to comply with study requirements and visit schedule

Exclusion Criteria

revious corneal surgery or pathology
Active or history of chronic or recurrent inflammatory eye disease in either eye
Ocular pain in either eye
Proliferative diabetic retinopathy in either eye
Significant macular pathology detected on macular optical coherence tomography evaluation at the screening visit in either eye
Laser or incisional ocular surgery during the study period and 6 months prior in either eye
Prescription and OTC ophthalmic mast cell stabilizers and antihistamines within 21 days prior to Screening and throughout the study period (systemic mast cell stabilizers are allowed, and systemic antihistamines are permitted)
Chronic daily use (defined as > 7 consecutive days at the recommended dosing frequency) of systemic narcotics for any chronic pain syndrome (eg, fibromyalgia, rheumatoid arthritis, etc.) during the study period
Ophthalmic artificial tear drop use within 2 hours prior to any study visit. Any OTC artificial tear (preserved or unpreserved) should be continued at the same frequency and with no change in drop brand
Use of any topical prescription ophthalmic medications (including cyclosporine [Restasis, Cequa] or topical lifitegrast [Xiidra], steroids, nonsteroidal anti- inflammatory drugs [NSAIDs], anti-glaucoma medications within 7 days or during study period
Participation in any drug or device clinical investigation within 30 days prior to entry into this study and/or during the period of study participation
Corticosteroids (intranasal, inhaled, topical dermatological, and perianal steroids) within 30 days prior to entry in the study are not permitted
Pregnant or breast-feeding women, women who wish to become pregnant during the length of study participation, or women of child-bearing potential
Use of systemic NSAID greater than 375 mg per day
Glaucoma or is on medications to treat glaucoma
Ocular Hypertension, defined as IOP of >21 mmHg, is on medications to treat hypertension or has a history of IOP spikes in either eye including steroid-related IOP increases
Presence of nasolacrimal duct obstruction or history of cauterization of the Punctum
Active epiphora or clinically significant dry eye syndrome
Know allergy or sensitivity to the investigational product or its components
The Investigator determines that the subject should not be included for reasons not already specified (e.g, systemic or other ocular disease/abnormality) if the health of the subject or the validity of the study outcomes may be compromised by the subject's enrollment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note